Chief Commercial Officer
Dave Backer joined Oxford Biomedica in September 2021 as Chief Commercial Officer, overseeing Oxford Biomedica’s Contract Development and Manufacturing Organisation (CDMO) as it expands beyond Lentiviral manufacturing into other vectors, including Adeno and AAV.
He has been involved in gene therapy and cell therapies for almost 25 years, starting as owner and founder of Molecular Medicine BioServices, a CDMO that started in the late 1990s focusing on GMP manufacturing of viral vectors. Dave broadened out into cell therapy and gene editing as Head of Commercial Development within MilliporeSigma’s ‘Promise Venture’ that focused on cell and gene therapy products and services.
Most recently, Dave was SVP of Commercial Development at ElevateBio, a technology company that centralises Chemistry, Manufacturing and Control related functions for partially or wholly owned companies, as well as more traditional Contract Manufacturing Organisation services for select strategic partners.